ASH FDA Collaboration

Advocacy Leadership Institute

Congressional Fellowship

Fight4Hematology Social Media Toolkit

Letter to the Editor Toolkit

Voices

Research Saves Lives

DANC

Iron Deficiency Initiative

Precision Medicine Initiative

ASH Center for Sickle Cell Disease Initiatives

Hotel Information

Testimony and Correspondence

Policy Statements

Federal Rule Summaries

Award Recipients

ASH Honorific Awards

ASH Abstract Achievement Awards and Outstanding Abstract Achievement Awards

Registration Information

Commercial Support

Commercial Support Opportunitities

Satellite Symposia

Satellite Symposia in Latin America

Drug Resources

Hematology Quality Measures

Clinical Practice Guidelines

Decision Aids

Hematology In-Service Exam

Fundamentals for Hematology Fellows

ASH Ambassador Program

Gene Table

ASH HematOmics Program (ASHOP) 

ASH Agenda for Hematology Research

Blood Basics

Hematology Glossary

Find a Hematologist

Continuing Medical Education (CME) Opportunities

Corporate Supporters

Abstracts

Host a Satellite Symposium

Exhibit at Highlights of ASH in North America

Hematology Inclusion Pathway

Be a Mentor

Mentorship Resources

Hotel and Travel Information

Schedule and Program

Meeting and Presenter Resources

Talking With Your Doctor

No content found. Try adjusting your filters.

No products found. Try different filters.

normal

As of June 2014, GlaxoSmithKline discontinued its patient access program for fondaparinux. ASH has not located any foundations that specifically offer assistance for patients requiring fondaparinux.

Access Programs for Fondaparinux

Drug Company Assistance

Foundation Assistance